Dapansutrile - Olatec Therapeutics

Drug Profile

Dapansutrile - Olatec Therapeutics

Alternative Names: OLT-1177

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Olatec Industries
  • Developer Olatec Therapeutics
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Inflammasome inhibitors; Interleukin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Musculoskeletal pain; Schnitzler syndrome
  • Phase I Heart failure
  • Preclinical Myocardial reperfusion injury

Most Recent Events

  • 16 May 2018 Phase-I clinical trials in Heart failure in USA (PO) (NCT03534297)
  • 16 May 2018 Olatec Therapeutics plans a phase I trial for Heart Failure in USA , (NCT03534297)
  • 07 Mar 2018 Phase-II clinical trials in Schnitzler syndrome (Treatment-experienced, In adults, In the elderly) in Netherlands (PO) (EudraCT-2017-003282-98)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top